MAP2K3 and non-small cell lung carcinoma: Therefore, we next asked if the other main activator of p38 MAPK, MKK3, could be implicated in the selective cDDP-mediated-activation of p38 MAPK and the resistance to this drug observed in our model of NSCLC derived cell lines.